Back

Effect of SGLT2i on myocardial remodeling due to cardiorenal syndrome in rat model of heart failure

19 May 2025 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Pathophysiology and treatment Heart Failure HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Matus Sykora

Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava (Slovakia)

6 More presentations in this session

Presentation thumbnail
Inflamed atrial tissues of patients with atrial fibrillation are characterized by pro-oxidant and pro-remodeling responses: synergistic inhibition by an SGLT2 inhibitor plus a GLP-1R activation
Doctor W. Fakih (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Mural cell dysfunction contributes to diastolic heart failure by promoting endothelial dysfunction and vessel remodeling
Professor E. Jones (Leuven, BE)
Abstract Slides Video
Presentation thumbnail
L-PGDS/ PGD2 is a regulator of cardiac metabolism during aging?
Doctor L. Savchenko (Toulouse, FR)
Abstract Slides Video
Presentation thumbnail
Circulating low-grade inflammation in human pulmonary arterial hypertension promotes eNOS-NO/ROS imbalance: Involvement of the angiotensin and the endothelin pathways and prevention by EPA:DHA 6:1
Ms H. MUZAMMEL (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Reversal of age-related diastolic dysfunction by micronized purified flavonoid fraction in rats with attenuation of low-grade inflammation, eNOS-NO/ROS imbalance, and left ventricular fibrosis
Professor V. Schini-Kerth (Strasbourg, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Pathophysiology and treatment

The Event

Event poster

Heart Failure 2025

19 May 2025 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Empagliflozin halts deleterious right ventricular remodeling in a model of rats with right ventricular dysfunction
thumbnail
Congress Presentation
Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study
thumbnail
Congress Presentation
Impact of dapagliflozin on exercise-induced hypertrophy: insights from a rodent model of athlete's heart

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources